Quest Diagnostics/SmithKline Beecham
This article was originally published in The Gray Sheet
Executive SummaryDelay of Quest's $1.3 bil. acquisition of SB's clinical laboratory operations over the issue of SB's access to Quest's clinical lab information database (1"The Gray Sheet" July 12, In Brief) is resolved with Quest's granting to SB non-exclusive rights to use the database, Quest says Aug. 9. As part of the agreement, Quest will receive a minority interest in a company that SB will form to sell information products and services. The transaction is expected to close within two weeks
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.